$IMCR

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Regulation FD Disclosure. Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US,

Immunocore (NASDAQ:IMCR) reported Q2 updates on tebentafusp (KIMMTRAK). At AACR, it cited 5-year overall survival of 16% vs 8% in HLA-A*02:01-positive metastatic uveal melanoma. TEBE-AM enrollment nears 540; topline data expected end-2026. Q2 R&D was $74M, net loss just under $1M, cash $880M. Rebates expected ~$120M in H2 2026.

Immunocore Holdings (IMCR) reported Q2 2026 EPS of a loss of $0.02, wider than the Zacks Consensus loss of $0.01. Revenue rose 18.3% Y/Y to $115.9 million, beating the $114 million estimate, driven by Kimmtrak net product sales. Management cited about $6 million of US distributor inventory stocking as a Q3 headwind.

Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma nearing

Immunocore Holdings (NASDAQ:IMCR) said May 31 it updated Phase 1/2 trial results for brenetafusp in heavily pretreated advanced melanoma, presented in a 2026 ASCO poster. The company reported a 6-month overall survival rate of 87% and a 52% disease control rate in HLA-A*02:01-positive patients, including those with primary PD-1 resistance, and reaffirmed Phase 3 PRISM-MEL-301 plans combining brenetafusp 160 mcg with nivolumab.

Immunocore reported updated Phase 1/2 brenetafusp data in heavily pretreated HLA-A*02:01-positive advanced melanoma at ASCO 2026. In 66 monotherapy patients, 6-month OS was 87% and disease control rate 52% (ORR 12%); median OS was 14.3 months. The company said results supported a 160 mcg dose for Phase 3 PRISM-MEL-301 and that safety was generally well tolerated.

Immunocore Holdings Plc has filed to sell 69,271 ADRs through a same-day cashless exercise and sale scheduled for May 26, 2026, with cash settlement brokered by J.P. Morgan Securities LLC. The filing also details recent sales by David Berman, including 11,832 ADRs sold on March 11, 2026, 25,000 on April 8, 2026, and 65,000 on May 21, 2026. The transaction is reported as having a neutral filing impact and sentiment, outlining key figures and definitions related to the Form 144 filing process.

Immunocore Holdings plc (IMCR) reported a profitable Q1 2026 with revenues of US$106.68 million and net income of US$12.97 million, alongside a US$76.48 million shelf registration for shares linked to its employee share ownership plan. This marked a shift to profitability after a loss in 2025 and indicates the company's focus on balancing growth, employee incentives, and capital access. The article suggests investors will now focus on the sustainability of this profitability and the ongoing clinical and commercial progress of KIMMTRAK, the company's main revenue driver, amidst rising R&D spending.

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity ...

Although the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.